
Dexcom

research spotlight

Comparing Continuous Glucose Monitoring (CGM) and Blood Glucose Monitoring (BGM) in Adults With Inadequately Controlled, Insulin-Treated Type 2 Diabetes: A 12-Month, Single-Center, Randomized Controlled Trial¹





* CGM - Continuous glucose monitoring, BGM - Blood glucose monitoring, TIR - Time in range (70-180 mg/dL), TAR - Time above range (>250 mg/dL) The mean active sensor time assessed during the last blinded CGM at 12-month follow-up was 96.3% † Group results from baseline to 12 months. ‡ (95% CI: 4.6; 25.9)% (P = 0.006) § (P = 0.006)


1. Lind N, et al. Diabetes Care 2019;42(8):1593-1603; doi: 10.2337/dci19-0028

GLYCEMIC AND METABOLIC OUTCOMES

When compared to BGM, CGM* use was associated with significantly improved outcomes.⁺ The improvements in A1C together with a decrease in total daily dose (TDD) of insulin, BMI and body weight was achieved without increasing other glucose-lowering treatments.¹







Participants in the 7.5% CGM group no longer required insulin for treatment at 12 months $(p=0.13).^{1}$

Key Takeaways for Dexcom CGM

- Significant improvement of TIR² in the Dexcom RT-CGM treated group compared to BGM treatment at 6 months which sustained until 12 months. (6 months: 12.4% TIR improvement (2 h 59 mins/day), P=0.021. 12 months: 15.2% TIR improvement (3 h 39 mins/day), P=0.006).¹
- The empowerment of people to make informed changes in their lifestyle is supported by the betweengroup difference in TIR peaking during the day and changes in diet and activity.¹
- Treatment de-escalation is supported by significant reduction of total daily dose of insulin (TDD). and a tendency to lower MDI and lower insulin dependency, without increase in other glucose-lowering treatments.
- Dexcom RT-CGM significantly improved glycemic, and self-reported metabolic participant outcomes compared to BGM in adults with insulin-treated type 2 diabetes.

Minimal education was needed to empower **\\$**` self-managed behavior change.¹

increase in TBR.¹

The increase of TIR was achieved without an



••••

Participants self-reported greater improvements in:

- General well-being
- Diabetes related distress
- Treatment and monitoring satisfaction.¹

Dexcom

* CGM - Continuous glucose monitoring, BGM - Blood glucose monitoring, TIR - Time in range (70-180 mg/dL), TAR - Time above range (>250 mg/dL). The mean active sensor time assessed during the last blinded CGM at 12-month follow-up was 96.3% † Group results from baseline to 12 months. ‡ (95% CI: 4.6; 25.9)% (P = 0.006) § (P = 0.006) 1. Nanna Lind, Merete B. Christensen, Dorte L. Hansen, and Kirsten Nørgaard, Diabetes Care 2024;47(5):1-9 | https://doi.org/10.2337/dc23-2194 2. Battelino T, Danne T, Bergenstal RM, et al. Diabetes Care 2019;42(8):1593-1603; doi: 10.2337/dc19-0028

Dexcom is a registered trademark of Dexcom, Inc. in the United States and/or other countries. @2024 Dexcom, Inc. All rights reserved. MAT-3802 v1.0